- Home
- Publications
- Publication Search
- Publication Details
Title
Drug development for Alzheimer’s disease: review
Authors
Keywords
-
Journal
JOURNAL OF DRUG TARGETING
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2018-05-07
DOI
10.1080/1061186x.2018.1474361
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
- (2018) Christopher H. van Dyck BIOLOGICAL PSYCHIATRY
- Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
- (2017) Petr Novak et al. LANCET NEUROLOGY
- Solanezumab: too late in mild Alzheimer's disease?
- (2017) The Lancet Neurology LANCET NEUROLOGY
- Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential
- (2017) Ana Marta de Matos et al. MEDICINAL RESEARCH REVIEWS
- New Hydroxyquinoline-Based Derivatives as Potent Modulators of Amyloid-β Aggregations
- (2016) Chin-Lan Fu et al. ARCHIV DER PHARMAZIE
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
- (2016) Laia Montoliu-Gaya et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
- (2016) Susanna Eketjäll et al. JOURNAL OF ALZHEIMERS DISEASE
- Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease
- (2016) Florence Pasquier et al. JOURNAL OF ALZHEIMERS DISEASE
- Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease
- (2016) Jack D. Scott et al. JOURNAL OF MEDICINAL CHEMISTRY
- Gamma Secretase Modulators: New Alzheimer’s Drugs on the Horizon?
- (2016) Matthew G. Bursavich et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
- (2016) Serge Gauthier et al. LANCET
- A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma
- (2016) Jennifer L. McQuade et al. MELANOMA RESEARCH
- Autophagy in Neurodegenerative Diseases and Metal Neurotoxicity
- (2016) Ziyan Zhang et al. NEUROCHEMICAL RESEARCH
- Dysfunction of NMDA receptors in Alzheimer’s disease
- (2016) Yan Zhang et al. NEUROLOGICAL SCIENCES
- Therapeutic strategies for Alzheimer's disease in clinical trials
- (2016) Justyna Godyń et al. Pharmacological Reports
- How neuroinflammation contributes to neurodegeneration
- (2016) R. M. Ransohoff SCIENCE
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS -amyloid in animal models and in Alzheimers disease patients
- (2016) M. E. Kennedy et al. Science Translational Medicine
- ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension
- (2016) Laura M. Gault et al. Alzheimers Research & Therapy
- Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
- (2016) Rik Vandenberghe et al. Alzheimers Research & Therapy
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies
- (2015) Ann J. Barbier et al. CLINICAL THERAPEUTICS
- Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease
- (2015) Charles R. Harrington et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Cu(II) enhances the effect of Alzheimer’s amyloid-β peptide on microglial activation
- (2015) Fengxiang Yu et al. Journal of Neuroinflammation
- Immune attack: the role of inflammation in Alzheimer disease
- (2015) Frank L. Heppner et al. NATURE REVIEWS NEUROSCIENCE
- CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid
- (2015) V. Porrini et al. NEUROSCIENCE
- CSF amyloid lowering in human volunteers after 14 days’ oral administration of the novel BACE1 inhibitor E2609
- (2014) Bruce Albala et al. Alzheimers & Dementia
- Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
- (2014) Christiane Reitz et al. BIOCHEMICAL PHARMACOLOGY
- Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
- (2014) Aaron H Burstein et al. BMC Neurology
- Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
- (2014) Francesco Panza et al. Expert Review of Clinical Immunology
- RAGE Ligation Affects T Cell Activation and Controls T Cell Differentiation
- (2014) Y. Chen et al. JOURNAL OF IMMUNOLOGY
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
- (2014) Robert Vassar Alzheimers Research & Therapy
- The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
- (2013) Patrick L. McGeer et al. ACTA NEUROPATHOLOGICA
- Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial
- (2013) Heii Arai et al. Alzheimers & Dementia
- A review on cholinesterase inhibitors for Alzheimer’s disease
- (2013) Preet Anand et al. ARCHIVES OF PHARMACAL RESEARCH
- BACE1 as a Therapeutic Target in Alzheimer’s Disease: Rationale and Current Status
- (2013) Genevieve Evin et al. DRUGS & AGING
- Systematic Proteomic Analysis Identifies β-Site Amyloid Precursor Protein Cleaving Enzyme 2 and 1 (BACE2 and BACE1) Substrates in Pancreatic β-Cells
- (2013) Ina Stützer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects
- (2013) Yanke Yu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immunotherapy for Alzheimer’s disease: hoops and hurdles
- (2013) Cynthia A Lemere Molecular Neurodegeneration
- Semagacestat's fall: where next for AD therapies?
- (2013) NATURE MEDICINE
- Alzheimer disease therapy—moving from amyloid-β to tau
- (2013) Ezio Giacobini et al. Nature Reviews Neurology
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
- (2013) Clara Theunis et al. PLoS One
- E2012-Induced Cataract and Its Predictive Biomarkers
- (2013) K. Nakano-Ito et al. TOXICOLOGICAL SCIENCES
- β-Secretase: its biology as a therapeutic target in diseases
- (2013) Haibo Wang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Animal Models of Alzheimer Disease
- (2013) F. M. LaFerla et al. Cold Spring Harbor Perspectives in Medicine
- First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing
- (2012) Robert Lai et al. Alzheimers & Dementia
- Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
- (2012) Martin Farlow et al. Alzheimers & Dementia
- Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease
- (2012) Henrik Zetterberg ARCHIVES OF NEUROLOGY
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment
- (2012) Jun Cai et al. EMBO Molecular Medicine
- New Aminoimidazoles as β-Secretase (BACE-1) Inhibitors Showing Amyloid-β (Aβ) Lowering in Brain
- (2012) Ylva Gravenfors et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- Amyloid Precursor Protein Processing and Alzheimer's Disease
- (2011) Richard J. O'Brien et al. Annual Review of Neuroscience
- Memantine in dementia: a review of the current evidence
- (2011) Nathan Herrmann et al. EXPERT OPINION ON PHARMACOTHERAPY
- Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
- (2011) Juan Manuel Domínguez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification and biology of β-secretase
- (2011) Patty C. Kandalepas et al. JOURNAL OF NEUROCHEMISTRY
- E2012: A novel gamma-secretase modulator-pharmacology part
- (2010) Toshihide Hashimoto et al. Alzheimers & Dementia
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?
- (2010) Cynthia A. Lemere et al. Nature Reviews Neurology
- Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor
- (2010) Kevin W. Gillman et al. ACS Medicinal Chemistry Letters
- Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy
- (2009) Alfred Maelicke et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing
- (2009) A. Schneeberger et al. Journal of Nutrition Health & Aging
- Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
- (2008) Lars Lannfelt et al. LANCET NEUROLOGY
- Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
- (2008) Paul A. Adlard et al. NEURON
- Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease
- (2008) Ilya Bezprozvanny et al. TRENDS IN NEUROSCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started